Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three-batch Process Validation Lives on in Europe

This article was originally published in The Gold Sheet

Executive Summary

The European Medicines Agency’s final process validation guidance fails to fully incorporate science- and risk-based approaches, asserts Europe’s pharmaceutical industry. The EMA is still collecting comments on the revised Annex 15 that covers the qualification and validation of facilities used in manufacturing.

Advertisement

Related Content

Industry Urges EU to Align Draft Validation Guidance with ICH and FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS000829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel